Literature DB >> 11755118

Inhibition of protein kinase D by resveratrol.

R S Haworth1, M Avkiran.   

Abstract

Protein kinase D (PKD) is a member of the protein kinase C (PKC) superfamily with distinctive structural, enzymological and regulatory properties. Identification of the cellular function(s) of PKD has been hampered by the absence of a selective inhibitor. Recently, Stewart et al. showed that resveratrol inhibited PKD, but not various PKC isoforms, in vitro. Here we confirmed that the activity of PKD is indeed inhibited in vitro by resveratrol (IC(50) approximately 200 microM). Additionally, we assessed the inhibition by resveratrol of PKD activity in intact cells, by Western blotting with a phosphospecific PKD antibody which recognizes the autophosphorylated enzyme. In this setting, very high concentrations of resveratrol were required to achieve inhibition of PKD autophosphorylation (IC(50) approximately 800 microM). Since resveratrol produces other pharmacological effects (e.g., cyclooxygenase inhibition) at lower concentrations than those required to inhibit PKD in intact cells, its value as a selective tool to investigate the cellular function(s) of PKD is questionable.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11755118     DOI: 10.1016/s0006-2952(01)00807-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.

Authors:  Kuzhuvelil B Harikumar; Ajaikumar B Kunnumakkara; Nobuo Ochi; Zhimin Tong; Amit Deorukhkar; Bokyung Sung; Lloyd Kelland; Stephen Jamieson; Rachel Sutherland; Tony Raynham; Mark Charles; Azadeh Bagherzadeh; Azadeh Bagherazadeh; Caroline Foxton; Alexandra Boakes; Muddasar Farooq; Dipen Maru; Parmeswaran Diagaradjane; Yoichi Matsuo; James Sinnett-Smith; Juri Gelovani; Sunil Krishnan; Bharat B Aggarwal; Enrique Rozengurt; Christopher R Ireson; Sushovan Guha
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

Review 2.  Protein kinase D as a potential new target for cancer therapy.

Authors:  Courtney R LaValle; Kara M George; Elizabeth R Sharlow; John S Lazo; Peter Wipf; Q Jane Wang
Journal:  Biochim Biophys Acta       Date:  2010-05-24

3.  Resveratrol, an effective regulator of ovarian development and oocyte apoptosis.

Authors:  X-X Kong; Y-C Fu; J-J Xu; X-L Zhuang; Z-G Chen; L-L Luo
Journal:  J Endocrinol Invest       Date:  2011-07-07       Impact factor: 4.256

4.  Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome.

Authors:  Stefan Uhle; Ohad Medalia; Richard Waldron; Renate Dumdey; Peter Henklein; Dawadschargal Bech-Otschir; Xiaohua Huang; Matthias Berse; Joseph Sperling; Rüdiger Schade; Wolfgang Dubiel
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

5.  Identification of glutathione sulfotransferase-pi (GSTP1) as a new resveratrol targeting protein (RTP) and studies of resveratrol-responsive protein changes by resveratrol affinity chromatography.

Authors:  Tze-Chen Hsieh; Zhirong Wang; Haiteng Deng; Joseph M Wu
Journal:  Anticancer Res       Date:  2008 Jan-Feb       Impact factor: 2.480

6.  Protein kinase D controls the integrity of Golgi apparatus and the maintenance of dendritic arborization in hippocampal neurons.

Authors:  Katalin Czöndör; Kornelia Ellwanger; Yannick F Fuchs; Sylke Lutz; Márton Gulyás; Isabelle M Mansuy; Angelika Hausser; Klaus Pfizenmaier; Katalin Schlett
Journal:  Mol Biol Cell       Date:  2009-02-11       Impact factor: 4.138

7.  Design, Synthesis, and Biological Evaluation of PKD Inhibitors.

Authors:  Kara M George; Marie-Céline Frantz; Karla Bravo-Altamirano; Courtney R Lavalle; Manuj Tandon; Stephanie Leimgruber; Elizabeth R Sharlow; John S Lazo; Q Jane Wang; Peter Wipf
Journal:  Pharmaceutics       Date:  2011       Impact factor: 6.321

8.  Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene.

Authors:  S Sale; R D Verschoyle; D Boocock; D J L Jones; N Wilsher; K C Ruparelia; G A Potter; P B Farmer; W P Steward; A J Gescher
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

Review 9.  Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture.

Authors:  Keryn G Woodman; Chantal A Coles; Shireen R Lamandé; Jason D White
Journal:  Nutrients       Date:  2016-11-09       Impact factor: 5.717

10.  PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.

Authors:  Caroline Spasojevic; Elisabetta Marangoni; Sophie Vacher; Franck Assayag; Didier Meseure; Sophie Château-Joubert; Martine Humbert; Manale Karam; Jean Marc Ricort; Christian Auclair; Marie Regairaz; Ivan Bièche
Journal:  Oncotarget       Date:  2018-05-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.